|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||21.74|
|Dividend & Yield||1.03 (3.23%)|
|1y Target Est||N/A|
Roche sees 'mid-single' digit sales growth in second half.
In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.
A run of disappointing drug trials at Roche has left analysts suggesting the view from its new 41-storey office building in Basel has become more clouded, with little chance of management now upgrading its growth forecast next week, when it reports first-half earnings. "Their impact in the second half might limit Roche's chances of upgrading 2017 guidance," he said.